Renewable Design for Novel Coronavirus Rapid Test - Myoglobin – Joinstar

Kit Name: Myoglobin Detection Kit (Fluorescence Dry Quantitative Immunoassay)

Method: Fluorescence dry quantitative immunoassay

Assay measuring range: 2.4 ng/mL to 400.0 ng/mL

Incubation time: 14 minutes

Sample: Human serum, plasma and whole blood (EDTA-K2 anticoagulant)

Reference range: 

Storage and Stability: 

✭Detection Buffer is stable for 12 months at 2°C ~8°C. 

✭Sealed Test Device is stable for 12 months at 4°C～30°C.

•Myoglobin is an important intracellular pigment protein, similar to hemoglobin, that binds and releases oxygen ,which found in the cytoplasm of mammalian type I and II a skeletal and cardiac muscle tissue.
•Myo contains a polypeptide chain of 153 amino acid and cofactor heme, with a small molecular weight, and is rapidly released from infarcted cardiomyocytes after a myocardial infarction.
•Although Myo is not highly myocardial specific, it is rapidly released from necrotic myocardium after myocardial infarction and is highly sensitive. Negative Myo is particularly helpful in ruling out the diagnosis of AMI. Myo is also a sensitive and accurate indicator of reperfusion during thrombolytic therapy for AMI.

•《Expert Consensus on Acute Chest Pain Emergency Care2019》
Recommended laboratory examinations includes：
①Markers of myocardial injury: cTN, CK-MB/MB, MYO, hs-cTn, HFABP, IMA, MPO
②Cardiac function markers: BNP, NT-proBNP
③Demoglobulin markers: D-dimer (preferred screening indicator)
④Chest pain-related inflammatory markers: CRP, MPO, PCT
⑤Arterial blood gas analysis ⑥Blood biochemistry ⑦Biomarker combination
All patients with acute non-traumatic chest pain seen in the emergency department should be treated symptomatically and combined with myocardial injury markers, BNP/NT-proBNP and D-dimer as soon as possible if there are risk factors and morbidity characteristics of high-risk chest pain and at least one of the following three conditions, namely hemodynamic instability, electrocardiographic activity instability or heart failure, are present; if the above three conditions are not present, the diagnosis or differential diagnosis of the disease can be completed by targeted testing of one or two types of indicators according to the specific etiology, and then combined with other testing indicators after the diagnosis is confirmed.

•《Guidelines for the diagnosis and treatment of acute ST-segment elevation myocardial infarction (2010)》
Serum myocardial injury markers need to be detected: cTn is the most specific and sensitive myocardial injury marker of choice for the diagnosis of myocardial necrosis, usually begins to rise 2-4 h after the onset of STEMI symptoms, peaking at 10-24 h, and can continue to rise for 7-14 d. Myoglobin measurement is useful for early diagnosis, but the specificity is poor. Creatine kinase isoenzyme (CK-MB) has a high clinical specificity for determining myocardial necrosis, and its measured value exceeds the upper limit of normal and has dynamic changes in STEMI.

•The most important indicator for early negative exclusion of AMI.
Myoglobin, one of the earliest detectable markers after the onset of acute myocardial infarction (AMI), begins to be released into the blood within 1 hour after the onset of AMI. As its diagnostic specificity is not high, mainly negative results can be used for early exclusion diagnosis.
•More sensitive indicator for AMI recurrence monitoring and reperfusion therapy monitoring.
Myoglobin returns to baseline concentration within the first day after the attack and then rises rapidly when there is another infarction, forming a multi-peak phenomenon that can counteract the periodic spontaneous coronary reinfarction and reperfusion of locally ischemic myocardium
•Combined test for the four indicators of heart attack
The time of elevation of cTnI, CK-MB, Myo, and H-FABP in blood, time of reaching peak in blood, time to normalization, and clinical significance are different. The detection of AMI is not sufficient if a single indicator is tested. Therefore, simultaneous rapid detection of these three markers can improve early sensitivity and late specificity in the diagnosis of heart disease.